Biocon, on Tuesday, said it had received approval from the Drug Controller General of India (DCGI) to market its product ‘Itolizumab’, used in the treatment of psoriasis. “The company has received market authorisation from the DCGI for its novel biologic Itolizumab, anti-CD6 molecule, for the treatment of chronic plaque psoriasis,” Biocon said in a statement. This approval paves way for the launch of the drug later in 2013 in India, it added. — PTI